Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index.

Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study

Nguipdop-Djomo, Patrick, Heldal, Einar, Rodrigues, Laura Cunha, Abubakar, Ibrahim, Mangtani, Punam · 2016 · The Lancet Infectious Diseases

Abstract

Background Little is known about how long the BCG vaccine protects against tuberculosis. We assessed the long-term vaccine effectiveness (VE) in Norwegian-born individuals.Methods In this retrospective population-based cohort study, we studied Norwegian-born individuals aged 12-50 years who were tuberculin skin test (TST) negative and eligible for BCG vaccination as part of the last round of Norway's mandatory mass tuberculosis screening and BCG vaccination programme between 1962 and 1975. We excluded individuals who had tuberculosis before or in the year of screening and those with unknown TST and BCG status. We obtained TST and BCG information and linked it to the National Tuberculosis Register, population and housing censuses, and the population register for emigrations and deaths. We followed individuals up to their first tuberculosis episode, emigration, death, or Dec 31, 2011. We used Cox regressions to estimate VE against all tuberculosis and just pulmonary tuberculosis by time since vaccination, adjusted for age, time, county-level tuberculosis rates, and demographic and socioeconomic indicators.Findings Median follow-up was 41 years (IQR 32-49) for 83 421 BCG-unvaccinated and 44 years (41-46) for 297 905 vaccinated individuals, with 260 tuberculosis episodes. Tuberculosis rates were 3·3 per 100 000 person-years in unvaccinated and 1·3 per 100 000 person-years in vaccinated individuals. The adjusted average VE during 40 year follow-up was 49% (95% CI 26-65), although after 20 years, the VE was not significant (up to 9 years VE [excluding tuberculosis episodes in the first 2 years] 61% [95% CI 24-80]; 10-19 years 58% [27-76]; 20-29 years 38% [-32 to 71]; 30-40 years 42% [-24 to 73]). VE against pulmonary tuberculosis up to 9 years (excluding tuberculosis episodes in the first 2 years) was 67% (95% CI 27-85), 10-19 years was 63% (32-80), 20-29 years was 50% (-19 to 79), and 30-40 years was 40% (-46 to 76).Interpretation Findings are consistent with long-lasting BCG protection, but waning of VE with time. The vaccine could be more cost effective than has been previously estimated Funding Norwegian Institute of Public Health and London School of Hygiene & Tropical Medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(15)00400-4

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 2

  1. 2004, BCG vaccine. WHO position paper, Wkly Epidemiol Rec, 79, 27
  2. Gernez-Rieux, 1973, Protection conférée par le BCG pendant les vingt années suivant la vaccination, Bull World Health Organ, 48, 139

Cited by

See all 221

Metadata

Authors
Nguipdop-Djomo, P., Heldal, E., Rodrigues, L. C., Abubakar, I., & Mangtani, P.
Affiliations
  • Norwegian Institute of Public Health (NO)
  • London School of Hygiene & Tropical Medicine (GB)
  • University College London (GB)
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2016-02
Volume
16
Issue
2
Pages
219-226
ISSN
1473-3099 (ISSN-L)
OpenAlex
W2181978203
Cited by
202
References
41
Citations by year
2026: 14 · 2025: 15 · 2024: 26 · 2023: 13 · 2022: 18 · 2021: 30 · 2020: 24 · 2019: 21 · 2018: 13 · 2017: 17 · 2016: 9
FWCI
10.36
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
Funders
National Institute for Health and Care Research (SRF-2011-04-001, 08/17/01, 08/16/01)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
  • Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
Keywords
BCG vaccine, long-term vaccine protection, time since vaccination, pulmonary tuberculosis, tuberculosis incidence, tuberculin skin test, tuberculosis prevention, tuberculosis mortality, tuberculosis control policy, Norway
MeSH terms
Adolescent, Adult, Age Factors, BCG Vaccine, Child, Female, Humans, Male, Mass Screening, Middle Aged, Mycobacterium bovis, Norway, Population Surveillance, Retrospective Studies, Socioeconomic Factors, Time Factors, Tuberculosis, Cohort Studies, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. https://app.cochat.ai/papers/10.1016/s1473-3099(15)00400-4
The paper
Nguipdop-Djomo, P., Heldal, E., Rodrigues, L. C., Abubakar, I., & Mangtani, P. (2016). Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(15)00400-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.